U.S. research roundup: Alnylam Pharmaceuticals, Carvana, MongoDB
ALNY•Analysts revised ratings or price targets for several U.S.-listed companies on Wednesday, including cuts for Alnylam Pharmaceuticals and MongoDB and a split-adjusted target for Carvana.
1. Highlighted target changes
JPMorgan cut its target price for Alnylam Pharmaceuticals to $369 from $375, and D.A. Davidson lowered its MongoDB target to $415 from $465. Oppenheimer adjusted its Carvana target to $90 from $450 to reflect a 5-for-1 stock split.
2. Other analyst actions
Analysts also raised targets for AAR, Amplitude, Annexon, BioCryst Pharmaceuticals, CarMax, Carnival, Immix Biopharma and the Baldwin Insurance Group. They cut targets for AnaptysBio, Arthur J. Gallagher, Brown & Brown, Dow, Goosehead Insurance, Graphic Packaging, Hawkeye 360, Lamb Weston, Marsh & McLennan, Owens Corning, Ryan Specialty, Sarepta Therapeutics and Uranium Energy. Texas Capital Securities initiated coverage of Ionic Digital with a buy rating and a $98 target, and Rum Group with a buy rating and a $15 target; Stephens initiated Smithfield Foods at equal weight with a $22 target.
